Please login to the form below
psoriasis
This page shows the latest psoriasis news and features for those working in and with pharma, biotech and healthcare.
CHMP recommends eight new medicines for EU approval
MorphoSys. The CHMP has also recommended approval of UCB’s Bimzelx (bimekizumab) for the treatment of moderate-to-severe plaque psoriasis, while Genetech’s Byoovis (ranibizumab) also received a positive opinion
Latest news
-
US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case
arthritis and plaque psoriasis.
-
Amgen strikes $240m autoimmune deal with Evoq Therapeutics
Amgen’s autoimmune franchise includes psoriasis blockbuster Otezla (apremilast), which it picked up from Celgene after it merged with Bristol Myers Squibb in 2019. ... Otezla fits right into Amgen’s existing psoriasis and anti-inflammatory product
-
Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda
The initial therapies set to be tested within the COMMUNITY trial are Amgen’s psoriasis med Otezla (apremilast), UCB’s investigational myasthenia gravis treatment zilucoplan and Takeda’s hereditary angioedema drug
-
Novartis weathers the COVID-19 storm in Q3, lifts outlook
In addition, sales of the company’s plaque psoriasis treatment Cosentyx (secukinumab) increased by 7%, with its HER2-negative breast cancer therapy Kisqali (ribociclib) also growing by 50%.
-
J&J inks $6.5bn all-cash deal to acquire Momenta
J&J already has high stakes in the autoimmune disease market, with some of its existing products, including psoriasis med Stelara (ustekinumab), already reaching blockbuster status.
US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case
Amgen strikes $240m autoimmune deal with Evoq Therapeutics
Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda
Novartis weathers the COVID-19 storm in Q3, lifts outlook
J&J inks $6.5bn all-cash deal to acquire Momenta
More from news
Approximately 68 fully matching, plus 293 partially matching documents found.
Latest Intelligence
-
Innovation in a digital context is not about technology – it’s about people
Initially we explored the experiences of people with psoriasis. We worked with them to develop and refine the platform based on their digital needs. ... which not only meets the needs of our clients, but the needs of people with psoriasis, who deserve
-
20 for 2020 – Five pharma leaders to watch in 2020
Hudson had a distinguished career at Novartis, presiding over the launches and roll-outs of psoriasis blockbuster Cosentyx (secukinumab), spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec) and heart failure therapy
-
20 for 2020 – Five pharma companies to watch
AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite ... BMS had to
-
Integrating patient reported outcomes into clinical trials
patients on psoriasis drugs for years.
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
It gained US approval for moderate to severe plaque psoriasis in April, and for EU approval in that indication in early May. ... In May last year, approval for Skyrizi was filed in Japan for plaque psoriasis, psoriatic arthritis, pustular psoriasis and
Innovation in a digital context is not about technology – it’s about people
20 for 2020 – Five pharma leaders to watch in 2020
20 for 2020 – Five pharma companies to watch
Integrating patient reported outcomes into clinical trials
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
More from intelligence
Approximately 0 fully matching, plus 38 partially matching documents found.
Latest appointments
-
Creabilis names Catherine Moukheibir as chairman of the board
Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.
-
Ziarco appoints Mike Grey to board of directors
and psoriasis.
-
Michael Fleming joins biosimilars firm Coherus
of Amgen and Pfizer's big-selling arthritis and psoriasis drug Enbrel (etanercept).
-
XenoPort appoints chief medical officer
XenoPort will look to Dr Kim's experience as it prepares to advance its drug candidate XP23829, which is being studied as a treatment for psoriasis and/or relapsing forms of
-
Former Sanofi SVP to chair Idera
These programmes involve the company's TLR antagonist drug candidates, which Idera says have shown proof-of-concept in clinical trials and are set for further studies in psoriasis and other
Creabilis names Catherine Moukheibir as chairman of the board
Ziarco appoints Mike Grey to board of directors
Former Sanofi SVP to chair Idera
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
psoriasis had safer and more effective treatment options that delivered the life-changing potential for clear skin. ... In addition, recent data show moderate and severe psoriasis are often undertreated with more than 50% of patients
-
Living with psoriasis: a patient perspective
Clear skin is somewhat of a perceived fantasy for most people living with psoriasis. ... i] Psoraisis Patients Association – about psoriasis. Psoriasis Patients Association 2017.
-
Fishawack Health launches global ‘PsoriasIS NOT CONTAGIOUS’ mask campaign for World Psoriasis Day 2020
Fishawack Health launches global disease awareness campaign, supported by the community of Psoriasis Warriors to de-stigmatize psoriasis during the COVID-19 pandemic. ... diverse group of people living with psoriasis and a downloadable toolkit to help
-
September 2020: diversity and inclusion in clinical trials round-up
Our latest round-up takes a closer look at the different conditions where health disparities are present, such as more women living with multiple sclerosis (MS), and the cancer death rate being highest among Black people vs all other ethnic groups.
-
Mednet Group
Body image and mental health: The psoriasis connection. ... Our Medical Writer Alex Teahan has written a thought piece on the report, where he shines a spotlight on psoriasis in relation to mental health and body image issues.
Living with psoriasis: a patient perspective
September 2020: diversity and inclusion in clinical trials round-up
Mednet Group
More from PMHub
Approximately 12 fully matching, plus 20 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Blockchain for Tracking and Validating Medical Cannabis
- Improving Health Through Integrated & Personalized Patient Care
- Amanda Pritchard becomes NHS England’s first female chief executive
- GSK beats expectations thanks to strong vaccine sales in Q2
- AZ raises full-year guidance after completing Alexion acquisition in Q2
- Resilience acquires bluebird bio’s manufacturing facility as part of cell therapy alliance
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Onyx Health Launch Creative Studio After Record Year
- Amanda Pritchard becomes NHS England’s first female chief executive
- Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
